For more information regarding the SIgN Immunomonitoring Platform and services, please download a copy of our brochure here.
The comprehensive Immunomonitoring Platform combines genomic, proteomic and novel cell-based assays to generate a complete picture of the human immune response during the course of disease or therapy
Rapid technological development in the fields of proteomics, genomics and cellular analysis has led to an extraordinary arsenal of analytical tools available to translational researchers today. Each of these technologies, however, can only provide a detailed assessment of limited aspects of the human immune response. The ability to fully integrate complex data from multiple analytical modalities and to understand this data in the context of ongoing clinical progression is a central challenge of translational immunology. As such, SIgN developed the Immunomonitoring Platform, which consolidated Flow Cytometry, Mass Cytometry, Immunogenomics, Immunoinformatics and more recently, Functional Immune Imaging.
The SIgN Immunomonitoring Platform uses data management and mining solutions to integrate and exploit large volumes of patient-specific data. This systems approach is being used by SIgN researchers for both early discovery and preclinical studies to discover biomarkers or novel therapeutic interventions, as well as to monitor and assess clinical trials. The comprehensive Immunomonitoring Platform forms a core infrastructure component of the basic, translational and clinical research performed at SIgN (Figure 1).
Figure 1: SIgN Immunomonitoring Platform